Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 3, n° 6
pages 602-611 (décembre 1980)
Doi : 10.1016/S0190-9622(80)80074-0
Clinical and laboratory studies

The treatment of severe cystic acne with 13-cis -retinoic acid : Evaluation of sebum production and the clinical response in a multiple-dose trial

Lawrence N. Farrell, M.D., John S. Strauss, M.D. , Anna M. Stranieri, B.S.
 From the Department of Dermatology, University of Iowa College of Medicine, USA 

1Reprint requests to: Dr. John S. Strauss, Department of Dermatology, University Hospitals, Iowa City, IA 52242.

Fourteen patients with severe, treatment-resistant, nodulocystic acne have been treated with 13-cis -retinoic acid in a double-blind study. The patients were treated with either 0.1, 0.5, or 1.0 mg/kg/day of 13-cis -retinoic acid for 12 weeks. A marked dose-related decrease in sebum production, which was usually evident within 2 weeks of the onset of therapy, was observed in all patients. At a dose of 1.0 mg/kg/day of 13-cis -retinoic acid, sebum production was decreased to about 10% of the pretreatment value. Clinical improvement, as judged by counting the nodulocystic lesions and measuring their greatest diameters, was noted in all three groups. The most common clinical side effects were cheilitis, desquamation of the skin, and pruritus, but the side effects were not severe enough to require interruption of treatment. Laboratory abnormalities during therapy were minimal and also did not necessitate the cessation of therapy.

The full text of this article is available in PDF format.

* Supported in part by a grant from Hoffmann-La Roche Inc., and by a research grant (RO-1-AM-22083-02) from the United States Public Health Service.

Top of the page

© 1980  The American Academy of Dermatology, Inc.. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline